Overview

FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump

Status:
Completed
Trial end date:
2020-04-20
Target enrollment:
Participant gender:
Summary
This is an exploratory, single-center, randomized, open label, active-controlled, complete cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the Medtronic MiniMed 670G system in subjects with T1DM.
Phase:
Phase 3
Details
Lead Sponsor:
Texas Diabetes & Endocrinology, P.A.
Treatments:
Insulin
Insulin Aspart
Insulin degludec, insulin aspart drug combination
Insulin, Globin Zinc
Insulin, Long-Acting